Can You Take Tramadol with Diazepam?

Severity assessment

Major. Concomitant use significantly increases the risk of profound sedation, respiratory depression, coma, and death.

Mechanism (plain English)

Both diazepam and tramadol act on the central nervous system (CNS) to cause depression. Diazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA, a neurotransmitter that reduces brain activity), leading to sedative and muscle-relaxant effects. Tramadol, an opioid analgesic, works by binding to opioid receptors and also by inhibiting the reuptake of norepinephrine and serotonin, which contributes to its pain-relieving effects. When taken together, their combined CNS depressant effects are additive, leading to an increased risk of severe side effects, particularly profound sedation and life-threatening respiratory depression.

Evidence level

Regulator-flagged. (FDA, MHRA)

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): No pair-specific public advisory found. However, the Product Information for Diazepam states: "If diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents to be employed—particularly with compounds that may potentiate the action of diazepam, such as... narcotic analgesics..." [1]. The Product Information for Tramadol states: "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death." [2]
• MHRA / NICE (UK): The MHRA issued a Drug Safety Update in March 2020, reminding healthcare professionals that "Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together if there is no alternative and the benefits outweigh the risks. If co-prescribed, limit dosages and duration to the minimum required and monitor patients for signs of respiratory depression and sedation." [3]
• FDA / CDC (US): The FDA label for Tramadol Hydrochloride Tablets includes a boxed warning: "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tramadol hydrochloride tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation." [2] The FDA label for Diazepam also states: "If diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents to be employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as... narcotic analgesics..." [1]
• EMA (Europe): No specific EMA advisory for this exact pair was found, but general warnings regarding concomitant use of opioids and benzodiazepines are consistent across European regulatory bodies.

Clinical risk factors that elevate the danger

• Age: Elderly patients are at increased risk due to decreased renal function and increased sensitivity to CNS depressants.
• Pre-existing respiratory conditions: Patients with chronic respiratory insufficiency are more susceptible to respiratory depression.
• History of substance abuse: Individuals with a history of alcohol or drug abuse are at higher risk of addiction, abuse, and misuse.
• Higher doses or rapid titration: Increasing doses or rapid adjustments of either medication can exacerbate CNS and respiratory depression.
• Concomitant use of other CNS depressants: Alcohol, other sedatives, hypnotics, or other opioid analgesics further increase the risk.
• Hepatic impairment: Impaired liver function can lead to accumulation of diazepam and its metabolites, prolonging their effects.

What a patient should be told

• Serious risks: Taking diazepam and tramadol together can lead to severe drowsiness, slowed breathing, unresponsiveness, coma, and even death. It is crucial to understand these risks.
• Do not stop suddenly: If you have been taking these medications together, do not stop either medication abruptly without consulting your doctor. Sudden discontinuation can lead to withdrawal symptoms, which can be serious.
• Warning signs: Be aware of warning signs such as unusual dizziness, extreme sleepiness, difficulty breathing, confusion, or unresponsiveness. If you experience any of these, seek immediate medical attention.
• Discuss alternatives: Talk to your doctor or pharmacist about safer alternative treatments or strategies to manage your pain and anxiety. They may be able to adjust your medications or suggest different options.
• Urgent care triggers: If you or someone you know experiences shallow breathing, extreme drowsiness, inability to wake up, or limpness, call emergency services immediately.

Top 3 sources (with full citation)

1. FDA. (2021). VALIUM (diazepam) Tablets, USP, C-IV, Full Prescribing Information. U.S. Food and Drug Administration. Available at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4b0c9c0a-4274-4d56-a7a4-bc497916469c&type=pdf
2. FDA. (2025). TRAMADOL HYDROCHLORIDE Tablets, for oral use, C-IV, Full Prescribing Information. U.S. Food and Drug Administration. Available at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=93b12089-3a0f-4b57-abb1-2429cf31995d&type=pdf
3. MHRA. (2020, March 18). Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression. GOV.UK. Available at: https://www.gov.uk/drug-safety-update/benzodiazepines-and-opioids-reminder-of-risk-of-potentially-fatal-respiratory-depression

Notes for the reviewing pharmacist

While diazepam's anticonvulsant properties might theoretically mitigate tramadol-induced seizures, the primary concern with co-administration remains the profound and potentially fatal respiratory depression due to additive CNS depressant effects. This interaction is well-documented by major regulatory bodies (FDA, MHRA) and warrants extreme caution. Patients with a history of substance abuse, respiratory compromise, or advanced age are particularly vulnerable. Emphasize the importance of patient education regarding the risks, warning signs, and the critical need to avoid self-adjustment of doses or abrupt discontinuation. Alternative pain management strategies should be explored, and if co-prescription is deemed absolutely necessary, it should be for the shortest duration and at the lowest effective doses, with close monitoring for signs of respiratory depression and sedation. The TGA does not have a specific advisory for this pair, but their individual product information documents highlight the risks of combining with other CNS depressants. The information provided aligns with the general consensus across major regulatory bodies regarding the significant risks of co-prescribing opioids and benzodiazepines.